Genetic tests: Evolving policy questions

IEEE Technology and Society Magazine

Volumn 15, Issue 4, 1996, Pages 4-10

  Asch, David A ^a   Mennuti, Michael T ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE; PUBLIC POLICY; SOCIAL ASPECTS;

GENETIC TESTING; HUMAN GENOME PROJECT;

GENETIC ENGINEERING;

EID: 0030388783     PISSN: 02780097     EISSN: None     Source Type: Journal    
DOI: 10.1109/44.546452     Document Type: Article

References (40)

1. National Center for Human Genome Research, Understanding our Genetic Inheritance: The U.S. Human Genome Project, NIH Publication 90-1590. Springfield, VA: National Technical Information Service, 1990.
2. House of Representatives Committee on Government Operations, "Designing genetic information policy: the need for an independent policy review of the ethical, legal, and social implications of the human genome project," House of Representatives Rep. 102-478, April 1, 1992, p. 25.
3. G.J. Meissen, R.H. Myers, C.A. Mastromauro et al., "Predictive testing for Huntington's disease with use of a linked DNA marker," New Eng. J. Med., vol. 318, pp. 535-542, 1988.
4. J.M. Hall, M.K. Lee, B. Newman, J.E. Morrow, L.A. Anderson, B. Huey and M.C. King, "Linkage of early onset breast cancer to chromosome 17q21," Science, vol. 250. pp. 1684-1689, 1990
5. Y. Miki, J. Swensen, S. Shattuck-Eidens et al., "A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA 1," Science, vol. 266, pp. 66-71, 1994.
6. S.G. Nayfield, J.E. Karp, L.G. Ford, P.A. Dorr and B.S. Kramer, "Potential role of tamoxifen in prevention of breast cancer." J. Natl. Cancer Inst., vol. 83, pp. 1450-1459, 1991.
7. L.D. Zeigler and S.S. Kroll, "Primary breast cancer after prophylactic mastectomy," Amer. J. Clin. Oncol., vol. 14, pp. 451-454, 1991.
8. H. Nelson, S.H. Miller, D. Buck, R.J. Demuth, W.S. Fletcher and P. Buehler, "Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice, Plast. Reconstr. Surg., vol. 83, pp. 662-669, 1989.
9. J.E. Goodnight, J.M. Quagliana and L. Morton, "Failure of subcutaneous mastectomy to prevent the development of breast cancer," J. Surg. Oncol., vol. 26, pp. 198-201, 1984.
10. G. Cowley, "Family matters," Newsweek, pp. 46-52, December 6, 1993.
11. B.B. Biesecker, M. Boehnke, K. Calzone, D.S. Markel, J.E. Garber, F.S. Collins and B.L. Weber, "Genetic counseling for families with inherited susceptibility to breast and ovarian cancer," JAMA, vol. 269, pp. 1970-1974, 1993.
12. F.A. Millan, A. Curtis and M. Mennie, et al., "Prenatal exclusion testing for Huntington's disease: A problem of too much information," J. Med. Genetics, vol. 26, pp. 83-85, 1989.
13. M.Z. Pelias, "Duty to disclose in medical genetics: A legal perspective," Amer J. Med. Genetics, vol. 39, pp. 347-354, 1991.
14. G.A. Chase, R.R. Faden, N.A. Holtzman, et al., "The assessment of genetic risk by pregnant women; implications for genetic counseling. Soc. Biol., vol. 33, pp. 57-64, 1986.
15. B.A. Wilfond and N. Fost, "The cystic fibrosis gene: medical and social implications for heterozygote detection," JAMA, vol. 263, pp. 2777-2783, 1990.
16. D.A. Asch, J.P. Patton, J.C. Hershey and M.T. Mennuti, "Reporting the results of cystic fibrosis carrier screening," Amer. J. Obstet. Gynecol., vol. 168, pp. 1-6, 1993.
17. Y. Verlinsky, E. Pergament and C. Strom. "The preimplantation genetic diagnosis of genetic diseases," J. In Vitro Fert. and Embryo Transfer, vol. 7, pp. 1-5, 1990.
18. A.H. Handyside, J.G. Lesko, J.J. Tar'n, M.L. Winston and M.R. Hughes, "Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis," New Eng. J. Med., vol. 327, pp. 905-909, 1993.
19. J.L. Simpson and S.A. Carson, "Preimplantation genetic diagnosis," New Eng. J. Med., vol. 327, pp. 951-953, 1992.
20. A. Clarke, "Is non-directive genetic counseling possible?" Lancet, vol. 338, pp. 998-1002, 1991.
21. E. Singer, "Public attitudes toward genetic testing," Population Res. and Policy Rev., vol. 10, pp. 235-255, 1991.
22. P. Reilly, Genetics, Law and Social Policy. Cambridge, MA: Harvard Univ. Press, 1977.
23. L. Roberts, "One worked: The other didn't," Science, vol. 247, p. 18, 1990.
24. N. A. Holtzman, Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era. Baltimore, MD: Johns Hopkins Univ. Press, 1989, pp. 217-218.
25. B. Metz, "Matchmaking scheme solves Tay-Sachs problem," JAMA, vol. 258, pp. 2636-2639, 1987.
26. M. Angastiniotis, "Cyprus: Thalassaemia program," Lancet, pp. 119-129, 1990.
27. American Medical Association Council on Ethical and Judicial Affairs, "Use of genetic testing by employers," JAMA, vol. 266, pp. 1827-1830, 1991.
28. U.S. Congress, Office of Technology Assessment, Genetic Monitoring and Screening in the Workplace, OTA-BA-455. Washington DC: U.S. Government Printing Office, 1990, p. 83.
29. C.F. Reinhardt, "Genetic hypersusceptibility," J. Occup. Med., vol. 20, pp. 319-322, 1978.
30. U.S. Congress, Office of Technology Assessment, Genetic Monitoring and Screening in the Workplace, OTA-BA-455. Washington DC: U.S. Government Printing Office, 1990, p. 148
31. American Medical Association Council on Ethical and Judicial Affairs, "Use of genetic testing by employers," JAMA, vol. 266, pp. 1827-1830, 1991.
32. E. Draper, Risky Business: Genetic Testing and Exclusionary Practices in the Hazardous Workplace. Cambridge, MA: Cambridge Univ. Press, 1991.
33. United Automobile Workers v. Johnson Controls, Inc. 111 SC 1196, 1991.
34. American Medical Association Council on Ethical and Judicial Affairs, "Use of genetic testing by employers," JAMA, vol. 266, pp. 1827-1830, 1991.
35. U.S. Congress, Office of Technology Assessment, Genetic Monitoring and Screening in the Workplace, OTA-BA-455, Washington DC: U.S. Government Printing Office, 1990
36. U.S. Congress, Office of Technology Assessment, Cystic Fibrosis and DNA Tests: Implications for Carrier Screening, OTA-HA-532. Washington DC: U.S. Government Printing Office, Aug. 1992, p. 195.
37. C.T. Caskey, "New technology brings new ethical consideration," Legal and Ethical Issues Raised by the Human Genome Project (conference materials), Houston, TX, Mar. 7-9, 1991.
38. P.R. Billings, M.A. Kohn, M. de Cuevas, J. Beckwith, J.S. Alper and M.R. Natowicz, "Discrimination as a consequence of genetic testings," Amer. J. Human Genetics, vol. 50, pp. 476-482, 1992.
39. U.S. Congress, Office of Technology Assessment, Cystic Fibrosis and DNA Tests: Implications for Carrier Screening. OTA-BA-532. Washington DC: U.S. Government Printing Office. Aug. 1992, p. 33.
40. D.W. Light, "The practice and ethics of risk-related health insurance," JAMA. vol. 267, pp. 2503-2508, 1992.